Microbiome therapy gains market traction.
Sara
S
Reardon
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000382:microbiology / Q000628:therapy; D001709:Biotechnology / Q000191:economics* / Q000639:trends*; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000382:microbiology / Q000628:therapy; D003920:Diabetes Mellitus / Q000378:metabolism / Q000382:microbiology / Q000628:therapy; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000382:microbiology; D007449:Investments; D051379:Mice; D064307:Microbiota / Q000187:drug effects; D009103:Multiple Sclerosis / Q000382:microbiology / Q000628:therapy; D019158:N-Acetylneuraminic Acid / Q000494:pharmacology / Q000627:therapeutic use; D018720:Prevotella / Q000502:physiology; D019936:Probiotics / Q000008:administration & dosage / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use*
D019158:N-Acetylneuraminic Acid